

# Leendert A Trouw

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/89143/publications.pdf>

Version: 2024-02-01

219  
papers

9,826  
citations

29994

54  
h-index

43802

91  
g-index

255  
all docs

255  
docs citations

255  
times ranked

9423  
citing authors

#	ARTICLE	IF	CITATIONS
1	Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 17372-17377.	3.3	464
2	Production of complement components by cells of the immune system. <i>Clinical and Experimental Immunology</i> , 2017, 188, 183-194.	1.1	350
3	Complement activation and inhibition: a delicate balance. <i>Trends in Immunology</i> , 2009, 30, 83-90.	2.9	304
4	Citrullinated peptide dendritic cell immunotherapy in HLA risk genotypeâ€“positive rheumatoid arthritis patients. <i>Science Translational Medicine</i> , 2015, 7, 290ra87.	5.8	302
5	Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. <i>European Journal of Immunology</i> , 2002, 32, 1726.	1.6	276
6	Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 234-241.	0.5	225
7	Antiâ€“cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. <i>Arthritis and Rheumatism</i> , 2009, 60, 1923-1931.	6.7	212
8	Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 780-783.	0.5	185
9	Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. <i>Journal of Clinical Investigation</i> , 2004, 114, 679-688.	3.9	185
10	Glycan profiling of antiâ€“citrullinated protein antibodies isolated from human serum and synovial fluid. <i>Arthritis and Rheumatism</i> , 2010, 62, 1620-1629.	6.7	183
11	The influence of ACPA status and characteristics on the course of RA. <i>Nature Reviews Rheumatology</i> , 2012, 8, 144-152.	3.5	173
12	Age and Sex-Associated Changes of Complement Activity and Complement Levels in a Healthy Caucasian Population. <i>Frontiers in Immunology</i> , 2018, 9, 2664.	2.2	165
13	Role of complement and complement regulators in the removal of apoptotic cells. <i>Molecular Immunology</i> , 2008, 45, 1199-1207.	1.0	164
14	Brief Report: Antiâ€“Carbamylated Protein Antibodies Are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, 911-915.	6.7	164
15	Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 578-585.	0.5	161
16	Maturation of dendritic cells abrogates C1q production in vivo and in vitro. <i>Blood</i> , 2004, 103, 3813-3820.	0.6	157
17	The complement system as a potential therapeutic target in rheumatic disease. <i>Nature Reviews Rheumatology</i> , 2017, 13, 538-547.	3.5	147
18	Properdin Binds to Late Apoptotic and Necrotic Cells Independently of C3b and Regulates Alternative Pathway Complement Activation. <i>Journal of Immunology</i> , 2008, 180, 7613-7621.	0.4	128

#	ARTICLE	IF	CITATIONS
19	The Factor H Variant Associated with Age-related Macular Degeneration (His-384) and the Non-disease-associated Form Bind Differentially to C-reactive Protein, Fibromodulin, DNA, and Necrotic Cells. <i>Journal of Biological Chemistry</i> , 2007, 282, 10894-10900.	1.6	126
20	Antibody Response Against the Glomerular Basement Membrane Protein Agrin in Patients with Transplant Glomerulopathy. <i>American Journal of Transplantation</i> , 2005, 5, 383-393.	2.6	125
21	Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2012, 12, 318-322.	2.5	124
22	Complement activation by (auto-) antibodies. <i>Molecular Immunology</i> , 2011, 48, 1656-1665.	1.0	122
23	Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 188-193.	0.5	118
24	C4b-binding Protein and Factor H Compensate for the Loss of Membrane-bound Complement Inhibitors to Protect Apoptotic Cells against Excessive Complement Attack. <i>Journal of Biological Chemistry</i> , 2007, 282, 28540-28548.	1.6	117
25	Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1761-1768.	0.5	111
26	Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2017, 13, 331-339.	3.5	109
27	Anti-carbamylated Protein Antibodies Are Present Prior to Rheumatoid Arthritis and Are Associated with Its Future Diagnosis. <i>Journal of Rheumatology</i> , 2015, 42, 572-579.	1.0	107
28	Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. <i>Journal of Clinical Investigation</i> , 2004, 114, 679-688.	3.9	104
29	Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage. <i>Arthritis Research and Therapy</i> , 2015, 17, 25.	1.6	103
30	Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. <i>Autoimmunity Reviews</i> , 2014, 13, 225-230.	2.5	99
31	Regulation of Complement Activation by C-Reactive Protein: Targeting of the Inhibitory Activity of C4b-Binding Protein. <i>Journal of Immunology</i> , 2006, 176, 7612-7620.	0.4	98
32	Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 1323-1328.	6.7	93
33	C4b-binding protein binds to necrotic cells and DNA, limiting DNA release and inhibiting complement activation. <i>Journal of Experimental Medicine</i> , 2005, 201, 1937-1948.	4.2	92
34	Specific Inhibition of the Classical Complement Pathway by C1q-Binding Peptides. <i>Journal of Immunology</i> , 2001, 167, 7052-7059.	0.4	84
35	Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. <i>Current Opinion in Nephrology and Hypertension</i> , 2003, 12, 619-624.	1.0	83
36	Triple Positivity for Anti-citrullinated Protein Autoantibodies, Rheumatoid Factor, and Anti-carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1721-1731.	2.9	81

#	ARTICLE	IF	CITATIONS
37	The C4b-binding Protein-Protein S Complex Inhibits the Phagocytosis of Apoptotic Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 23869-23873.	1.6	78
38	Role of complement in innate immunity and host defense. <i>Immunology Letters</i> , 2011, 138, 35-37.	1.1	76
39	A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. <i>Molecular Immunology</i> , 2007, 44, 1835-1844.	1.0	73
40	Recognition of citrullinated and carbamylated proteins by human antibodies: specificity, cross-reactivity and the $\alpha$ -AMC-Senshu <sup>TM</sup> method. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 148-150.	0.5	73
41	Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1184-1190.	0.5	73
42	Anti-citrullinated protein antibodies have a low avidity compared with antibodies against recall antigens. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 373-379.	0.5	69
43	Circulating plasmablasts/plasmacells as a source of anticitrullinated protein antibodies in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1259-1263.	0.5	69
44	The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 339.	1.6	67
45	The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 112-118.	0.5	67
46	Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 209.	1.6	63
47	The ACPA recognition profile and subgrouping of ACPA-positive RA patients. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 268-274.	0.5	61
48	Rheumatoid factor isotypes in relation to antibodies against citrullinated peptides and carbamylated proteins before the onset of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 43.	1.6	61
49	Infiltrating dendritic cells contribute to local synthesis of C1q in murine and human lupus nephritis. <i>Molecular Immunology</i> , 2010, 47, 2129-2137.	1.0	60
50	Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies. <i>Clinical and Experimental Immunology</i> , 2003, 132, 32-39.	1.1	59
51	Rheumatoid arthritis-associated autoantibodies in non-rheumatoid arthritis patients with mucosal inflammation: a case-control study. <i>Arthritis Research and Therapy</i> , 2015, 17, 174.	1.6	59
52	Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I. <i>European Journal of Immunology</i> , 2010, 40, 172-185.	1.6	58
53	Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome. <i>Arthritis Research and Therapy</i> , 2012, 14, R185.	1.6	57
54	Type I Interferon Gene Response Is Increased in Early and Established Rheumatoid Arthritis and Correlates with Autoantibody Production. <i>Frontiers in Immunology</i> , 2017, 8, 285.	2.2	57

#	ARTICLE	IF	CITATIONS
55	Autoantibodies against mannose-binding lectin in systemic lupus erythematosus. <i>Clinical and Experimental Immunology</i> , 2003, 134, 335-343.	1.1	56
56	The interaction between HLA shared epitope alleles and smoking and its contribution to autoimmunity against several citrullinated antigens. <i>Arthritis and Rheumatism</i> , 2011, 63, 1823-1832.	6.7	55
57	Anti-C1q Autoantibodies, Novel Tests, and Clinical Consequences. <i>Frontiers in Immunology</i> , 2013, 4, 117.	2.2	55
58	A role for mannose-binding lectin dysfunction in generation of autoantibodies in systemic lupus erythematosus. <i>British Journal of Rheumatology</i> , 2005, 44, 111-119.	2.5	54
59	Genetic, molecular and functional analyses of complement factor I deficiency. <i>European Journal of Immunology</i> , 2009, 39, 310-323.	1.6	53
60	A common SNP in the CD40 region is associated with systemic lupus erythematosus and correlates with altered CD40 expression: implications for the pathogenesis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2184-2190.	0.5	53
61	C1q, antibodies and anti-C1q autoantibodies. <i>Molecular Immunology</i> , 2015, 68, 6-13.	1.0	53
62	Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1924-1932.	0.5	53
63	Autoantibodies against complement components and functional consequences. <i>Molecular Immunology</i> , 2013, 56, 213-221.	1.0	52
64	The risk of individual autoantibodies, autoantibody combinations and levels for arthritis development in clinically suspect arthralgia. <i>Rheumatology</i> , 2017, 56, 2145-2153.	0.9	50
65	Complement activation in Glioblastoma Multiforme pathophysiology: Evidence from serum levels and presence of complement activation products in tumor tissue. <i>Journal of Neuroimmunology</i> , 2015, 278, 271-276.	1.1	48
66	C4b-binding protein in Alzheimer's disease: Binding to A $\beta$ 1-42 and to dead cells. <i>Molecular Immunology</i> , 2008, 45, 3649-3660.	1.0	46
67	Distinct ACPA fine specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1461-1464.	0.5	45
68	Biomarkers for rheumatoid and psoriatic arthritis. <i>Clinical Immunology</i> , 2015, 161, 2-10.	1.4	45
69	Renal tubular epithelial cells modulate T-cell responses via ICOS-L and B7-H1. <i>Kidney International</i> , 2005, 68, 2091-2102.	2.6	44
70	TRAF1/C5, eNOS, C1q, but not STAT4 and PTPN22 gene polymorphisms are associated with genetic susceptibility to systemic lupus erythematosus in Turkey. <i>Human Immunology</i> , 2011, 72, 1210-1213.	1.2	44
71	Autoimmunity in rheumatoid arthritis: different antigensâ€”common principles. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, ii132-ii136.	0.5	44
72	Human neutrophil peptide-1 inhibits both the classical and the lectin pathway of complement activation. <i>Molecular Immunology</i> , 2007, 44, 3608-3614.	1.0	43

#	ARTICLE	IF	CITATIONS
73	Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study. <i>Arthritis Research and Therapy</i> , 2016, 18, 285.	1.6	43
74	Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts. <i>Arthritis Research and Therapy</i> , 2016, 18, 289.	1.6	43
75	Complement Component C1q as Serum Biomarker to Detect Active Tuberculosis. <i>Frontiers in Immunology</i> , 2018, 9, 2427.	2.2	43
76	Genetic variants in the region of the C1q genes are associated with rheumatoid arthritis. <i>Clinical and Experimental Immunology</i> , 2013, 173, 76-83.	1.1	41
77	Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1139-1144.	0.5	41
78	Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 270-276.	0.5	40
79	Autoantibodies to complement components. <i>Molecular Immunology</i> , 2001, 38, 199-206.	1.0	39
80	Both Complement and IgG Fc Receptors Are Required for Development of Attenuated Antiglomerular Basement Membrane Nephritis in Mice. <i>Journal of Immunology</i> , 2009, 183, 3980-3988.	0.4	39
81	Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes. <i>Arthritis Research and Therapy</i> , 2018, 20, 33.	1.6	39
82	Anti-C1q autoantibodies in murine lupus nephritis. <i>Clinical and Experimental Immunology</i> , 2004, 135, 41-48.	1.1	38
83	Complement production and regulation by dendritic cells: Molecular switches between tolerance and immunity. <i>Molecular Immunology</i> , 2008, 45, 4064-4072.	1.0	37
84	Complement Activation in Patients With Diabetic Nephropathy. <i>Kidney International Reports</i> , 2018, 3, 302-313.	0.4	37
85	Antibodies Specific for Carbamylated Proteins Precede the Onset of Clinical Symptoms in Mice with Collagen Induced Arthritis. <i>PLoS ONE</i> , 2014, 9, e102163.	1.1	37
86	Role of Anti-Carbamylated Protein Antibodies Compared to Anti-Citrullinated Protein Antibodies in Indigenous North Americans With Rheumatoid Arthritis, Their First-Degree Relatives, and Healthy Controls. <i>Arthritis and Rheumatology</i> , 2016, 68, 2090-2098.	2.9	36
87	Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 716-720.	0.5	35
88	The production and secretion of complement component C1q by human mast cells. <i>Molecular Immunology</i> , 2016, 78, 164-170.	1.0	34
89	Identification of carbamylated alpha 1 anti-trypsin (A1AT) as an antigenic target of anti-CarP antibodies in patients with rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 2017, 80, 77-84.	3.0	34
90	Pitfalls in the detection of citrullination and carbamylation. <i>Autoimmunity Reviews</i> , 2018, 17, 136-141.	2.5	34

#	ARTICLE	IF	CITATIONS
91	Different classes of anti-modified protein antibodies are induced on exposure to antigens expressing only one type of modification. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 908-916.	0.5	34
92	Marked variability in clinical presentation and outcome of patients with C1q immunodeficiency. <i>Journal of Autoimmunity</i> , 2015, 62, 39-44.	3.0	33
93	In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response. <i>Arthritis Research and Therapy</i> , 2019, 21, 28.	1.6	33
94	Anti-carbamylated protein antibodies: a specific hallmark for rheumatoid arthritis. Comparison to conditions known for enhanced carbamylation; renal failure, smoking and chronic inflammation. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1575-1576.	0.5	32
95	Complement levels and anti-C1q autoantibodies in patients with neuropsychiatric systemic lupus erythematosus. <i>Lupus</i> , 2016, 25, 878-888.	0.8	31
96	Role of anti-C1q autoantibodies in the pathogenesis of lupus nephritis. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 243-251.	1.4	30
97	C1q Deficiency and Neuropsychiatric Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2016, 7, 647.	2.2	30
98	New biomarkers in rheumatoid arthritis. <i>Netherlands Journal of Medicine</i> , 2012, 70, 392-9.	0.6	30
99	Factor H Autoantibodies in Patients with Antiphospholipid Syndrome and Thrombosis. <i>Journal of Rheumatology</i> , 2015, 42, 1786-1793.	1.0	29
100	Analysis of Binding Sites on Complement Factor I That Are Required for Its Activity. <i>Journal of Biological Chemistry</i> , 2010, 285, 6235-6245.	1.6	28
101	Breach of autoreactive B cell tolerance by post-translationally modified proteins. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1449-1457.	0.5	27
102	Anti-citrullinated protein antibodies in the diagnosis of rheumatoid arthritis (RA): diagnostic performance of automated anti-CCP-2 and anti-CCP-3 antibodies assays. <i>Clinical Rheumatology</i> , 2017, 36, 1487-1492.	1.0	27
103	Complement and renal disease. <i>Molecular Immunology</i> , 2003, 40, 125-134.	1.0	26
104	Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis. <i>Modern Rheumatology</i> , 2012, 22, 15-20.	0.9	26
105	Anti-carbamylated protein antibodies in rheumatoid arthritis patients of Asian descent: Fig. 1. <i>Rheumatology</i> , 2015, 54, 1930-1932.	0.9	25
106	Anticarbamylated protein (anti-CarP) antibodies are present in sera of juvenile idiopathic arthritis (JIA) patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 2053-2055.	0.5	24
107	Immune deposition of C1q and anti-C1q antibodies in the kidney is dependent on the presence of glomerular IgG. <i>Molecular Immunology</i> , 2003, 40, 595-602.	1.0	23
108	The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical. <i>Arthritis Research and Therapy</i> , 2017, 19, 115.	1.6	23

#	ARTICLE	IF	CITATIONS
109	Complement Inhibitor C4b-Binding Protein in Primary Sjögren's Syndrome and its Association With Other Disease Markers. <i>Scandinavian Journal of Immunology</i> , 2009, 69, 374-380.	1.3	22
110	Excretions/secretions from medicinal larvae ( <i>Lucilia sericata</i> ) inhibit complement activation by two mechanisms. <i>Wound Repair and Regeneration</i> , 2017, 25, 41-50.	1.5	22
111	Secretory form of rheumatoid arthritis-associated autoantibodies in serum are mainly of the IgM isotype, suggesting a continuous reactivation of autoantibody responses at mucosal surfaces. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 146-148.	0.5	22
112	Circulating C1q levels in health and disease, more than just a biomarker. <i>Molecular Immunology</i> , 2021, 140, 206-216.	1.0	22
113	The concentration of anticitrullinated protein antibodies in serum and synovial fluid in relation to total immunoglobulin concentrations. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1059-1063.	0.5	21
114	An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting. <i>Arthritis Research and Therapy</i> , 2015, 17, 276.	1.6	21
115	C1q-Dependent Dendritic Cell Cross-Presentation of In Vivo-Formed Antigen-Antibody Complexes. <i>Journal of Immunology</i> , 2017, 198, 4235-4243.	0.4	21
116	The isotype and IgG subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2017, 19, 190.	1.6	20
117	Complement activation and regulation in rheumatic disease. <i>Seminars in Immunology</i> , 2019, 45, 101339.	2.7	20
118	Expression and production of the SERPING1-encoded endogenous complement regulator C1-inhibitor in multiple cohorts of tuberculosis patients. <i>Molecular Immunology</i> , 2020, 120, 187-195.	1.0	19
119	Activation of the lectin pathway in murine lupus nephritis. <i>Molecular Immunology</i> , 2005, 42, 731-740.	1.0	18
120	The fine specificity of IgM anti-citrullinated protein antibodies (ACPA) is different from that of IgG ACPA. <i>Arthritis Research and Therapy</i> , 2011, 13, R195.	1.6	17
121	MRI-detected osteitis is not associated with the presence or level of ACPA alone, but with the combined presence of ACPA and RF. <i>Arthritis Research and Therapy</i> , 2016, 18, 179.	1.6	17
122	C-reactive protein in myocardial infarction binds to circulating microparticles but is not associated with complement activation. <i>Clinical Immunology</i> , 2010, 135, 490-495.	1.4	16
123	Anticarbamylated protein antibodies can be detected in animal models of arthritis that require active involvement of the adaptive immune system. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 949-950.	0.5	16
124	Complement component C1q is produced by isolated articular chondrocytes. <i>Osteoarthritis and Cartilage</i> , 2020, 28, 675-684.	0.6	16
125	C4b-Binding Protein Is Present in Affected Areas of Myocardial Infarction during the Acute Inflammatory Phase and Covers a Larger Area than C3. <i>PLoS ONE</i> , 2008, 3, e2886.	1.1	15
126	Identification of a novel non-coding mutation in C1qB in a Dutch child with C1q deficiency associated with recurrent infections. <i>Immunobiology</i> , 2015, 220, 422-427.	0.8	15



#	ARTICLE	IF	CITATIONS
127	Anti-carbamylated protein antibodies precede disease onset in monkeys with collagen-induced arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 246.	1.6	15
128	The role of complement activation in autoimmune liver disease. <i>Autoimmunity Reviews</i> , 2020, 19, 102534.	2.5	15
129	Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis. <i>Modern Rheumatology</i> , 2012, 22, 15-20.	0.9	15
130	The extensive glycosylation of the ACPA variable domain observed for ACPA-IgG is absent from ACPA-IgM. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1087-1088.	0.5	14
131	Glomerular C4d deposition can precede the development of focal segmental glomerulosclerosis. <i>Kidney International</i> , 2019, 96, 738-749.	2.6	14
132	Presence of Autoantibodies in Erosive Hand Osteoarthritis and Association with Clinical Presentation. <i>Journal of Rheumatology</i> , 2019, 46, 101-105.	1.0	14
133	Auto-antibodies to post-translationally modified proteins in osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2021, 29, 924-933.	0.6	14
134	Novel genetic association of the VTCN1 region with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 567-571.	0.5	13
135	Predictive factors of radiological progression after 2â€¦years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study. <i>RMD Open</i> , 2016, 2, e000172.	1.8	13
136	In RA, becoming seronegative over the first year of treatment does not translate to better chances of drug-free remission. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1836-1838.	0.5	12
137	Autoantibodies are major predictors of arthritis development in patients with anti-citrullinated protein antibodies and musculoskeletal pain. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 189-197.	0.6	12
138	<i>HLA-B*08</i> Identified as the Most Prominently Associated Major Histocompatibility Complex Locus for Anti-â€œCarbamylated Protein Antibodyâ€œPositive/Anti-â€œCyclic Citrullinated Peptideâ€œNegative Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 963-969.	2.9	12
139	Cross-reactivity of IgM anti-modified protein antibodies in rheumatoid arthritis despite limited mutational load. <i>Arthritis Research and Therapy</i> , 2021, 23, 230.	1.6	12
140	The anti-carbamylated protein antibody response is of overall low avidity despite extensive isotype switching. <i>Rheumatology</i> , 2018, 57, 1583-1591.	0.9	11
141	Systemic and pulmonary C1q as biomarker of progressive disease in experimental non-human primate tuberculosis. <i>Scientific Reports</i> , 2020, 10, 6290.	1.6	11
142	Association of anti-carbamylated protein antibodies with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. <i>Lancet</i> , The, 2015, 385, S44.	6.3	10
143	Mass-spectrometric identification of carbamylated proteins present in the joints of rheumatoid arthritis patients and controls. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 570-577.	0.4	10
144	The major risk alleles of age-related macular degeneration (AMD) in <i>CFH</i> do not play a major role in rheumatoid arthritis (RA). <i>Clinical and Experimental Immunology</i> , 2011, 166, 333-337.	1.1	9

#	ARTICLE	IF	CITATIONS
145	Does information on novel identified autoantibodies contribute to predicting the progression from undifferentiated arthritis to rheumatoid arthritis: a study on anti-CarP antibodies as an example. <i>Arthritis Research and Therapy</i> , 2018, 20, 94.	1.6	9
146	Carbamylation reduces the capacity of IgG for hexamerization and complement activation. <i>Clinical and Experimental Immunology</i> , 2020, 200, 1-11.	1.1	9
147	Autoantibodies against specific post-translationally modified proteins are present in patients with lupus and associate with major neuropsychiatric manifestations. <i>RMD Open</i> , 2022, 8, e002079.	1.8	9
148	Autoantibody testing to predict response to therapy in RA. <i>Nature Reviews Rheumatology</i> , 2016, 12, 566-568.	3.5	8
149	Arthritis autoantibodies in individuals without rheumatoid arthritis: follow-up data from a Dutch population-based cohort (Lifelines). <i>Rheumatology</i> , 2021, 60, 658-666.	0.9	7
150	Placental Complement Activation in Fetal and Neonatal Alloimmune Thrombocytopenia: An Observational Study. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6763.	1.8	7
151	The window of opportunity in ACPA-positive rheumatoid arthritis is not explained by ACPA characteristics. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1697-1698.	0.5	6
152	Short article. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 345-348.	0.8	6
153	Anti-“Carbamylated Protein Antibodies and Higher Baseline Disease Activity in Rheumatoid Arthritis” A Replication Study in Three Cohorts: Comment on the Article by Truchetet et al. <i>Arthritis and Rheumatology</i> , 2018, 70, 2096-2097.	2.9	6
154	The role of complement in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Current Opinion in Rheumatology</i> , 2019, 31, 3-8.	2.0	6
155	Serum autoantibodies directed against transglutaminase-2 have a low avidity compared with alloantibodies against gliadin in coeliac disease. <i>Clinical and Experimental Immunology</i> , 2014, 177, 86-93.	1.1	5
156	Inverse correlation between serum complement component C1q levels and whole blood type-1 interferon signature in active tuberculosis and QuantiFERON-1 positive uveitis: implications for diagnosis. <i>Clinical and Translational Immunology</i> , 2020, 9, e1196.	1.7	5
157	SAT0585...GEO-EPIDEMIOLOGY OF AUTOANTIBODIES IN RA: DIFFERENT PREVALENCES IN FOUR ETHNICALLY DIVERSE RA POPULATIONS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1251.1-1252.	0.5	5
158	Initial properdin binding contributes to alternative pathway activation at the surface of viable and necrotic cells. <i>European Journal of Immunology</i> , 2022, , .	1.6	5
159	Mass-spectrometric identification of carbamylated proteins present in the joints of rheumatoid arthritis patients and controls. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 570-577.	0.4	5
160	B-cell activating factor and IL-21 levels predict treatment response in autoimmune hepatitis. <i>JHEP Reports</i> , 2022, 4, 100460.	2.6	5
161	THU0114...Effect of Anti-Cyclic Citrullinated Peptide 2 Immunoglobulin M Serostatus on Efficacy Outcomes Following Treatment with Abatacept Plus Methotrexate in the Avert Trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 234.3-235.	0.5	4
162	Substitution of the quantitative serological component in the 2010 criteria for RA with qualitative presence of three autoantibodies yields similar performance: response to the article by Regueiro et al.. <i>Arthritis Research and Therapy</i> , 2020, 22, 85.	1.6	4

#	ARTICLE	IF	CITATIONS
163	Anti-CCP antibodies are a collection of ACPA that are cross-reactive to multiple citrullinated antigens. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, A8-A8.	0.5	3
164	The interaction between HLA SE alleles and smoking and its contribution to autoimmunity against several citrullinated antigens. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A1-A1.	0.5	3
165	Complex medical history of a patient with a compound heterozygous mutation in C1QC. <i>Lupus</i> , 2019, 28, 1255-1260.	0.8	3
166	Genetic variants of C1q are a risk for rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A17-A17.	0.5	2
167	ACPA production by circulating B cells isolated from peripheral blood of patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A33.1-A33.	0.5	2
168	A5.4â€¦Anti Carbamylated Protein Antibodies (Anti-CarP) Are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A31.2-A31.	0.5	2
169	Identification of Lifelines participants at high risk for development of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e43-e43.	0.5	2
170	Screening for two or three autoantibodies in persons at risk for RA: implications of current data for clinical practice. <i>Rheumatology</i> , 2019, 58, 914-915.	0.9	2
171	Long-term follow-up of patients with anti-cyclic citrullinated peptide antibody-positive connective tissue disease: a retrospective observational study including information on the HLA-DRB1 allele and citrullination dependency. <i>Arthritis Research and Therapy</i> , 2020, 22, 248.	1.6	2
172	Regulation of complement activation by C-reactive protein: Targeting of the inhibitory activity of C4b-binding protein. <i>Molecular Immunology</i> , 2007, 44, 241.	1.0	1
173	Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation. <i>Molecular Immunology</i> , 2008, 45, 4138-4139.	1.0	1
174	Genetic association and functional consequences of a common SNP in the CD40 region with systemic lupus erythematosus and rheumatoid arthritis in a homogeneous Greek population. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A14-A14.	0.5	1
175	Which elements of the criteria for RA are stable over time?. <i>Rheumatology</i> , 2011, 50, 248-249.	0.9	1
176	AB0096â€¦Presence of systemic arthritis autoantibodies in non-ra patients with severe periodontitis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A814.4-A815.	0.5	1
177	A5.14â€¦Homocitrulline-Reactive Antibodies can be Generated from Synovial B-Cells from ACPA-Negative RA Patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A35.1-A35.	0.5	1
178	A1.28â€¦Anti-carp antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors and smoking. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A11.3-A12.	0.5	1
179	A1.55â€¦Development of antibodies specific for carbamylated protein precedes disease onset in MICE with collagen-induced arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A23.2-A24.	0.5	1
180	Reply. <i>Arthritis and Rheumatology</i> , 2016, 68, 2826-2827.	2.9	1

#	ARTICLE	IF	CITATIONS
181	Complement component C1q as serum biomarker to detect active tuberculosis. <i>Molecular Immunology</i> , 2018, 102, 185.	1.0	1
182	Molecular and functional analysis of complement factor I mutations in atypical haemolytic uraemic syndrome patients. <i>Molecular Immunology</i> , 2008, 45, 4131.	1.0	0
183	Anti-citrullinated protein antibodies have a low avidity compared to antibodies against recall-antigens. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, A7-A7.	0.5	0
184	The major risk alleles of age related macular degeneration in CFH, do not play a major role in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A17-A18.	0.5	0
185	Distinct ACPA fine-specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A5-A5.	0.5	0
186	Low avidity anti-citrullinated protein antibodies (ACPA) are associated with high radiographic progression in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A60-A60.	0.5	0
187	Genetic variants of C1q are a risk for rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A54.1-A54.	0.5	0
188	The "Senshu"™ method often used to detect citrullinated proteins does not discriminate between citrullination and carbamylation. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A40.2-A40.	0.5	0
189	The ACPA IgM fine specificity differs from the ACPA IgG antigen-recognition profile. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A33.2-A33.	0.5	0
190	FR10005...Production of anti-citrullinated protein antibodies by B cell subsets isolated from peripheral blood of patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 312.2-312.	0.5	0
191	A5.29...Spontaneous Production of Anti-Citrullinated Protein Antibodies in Cultures of Peripheral Blood Mononuclear Cells and Synovial Fluid Mononuclear Cells Isolated from Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A41.1-A41.	0.5	0
192	A5.6...Anti-Carbamylated Protein Antibodies are Present in Mice with Collagen induced Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A32.1-A32.	0.5	0
193	A1.45...Hyperglycosylation of ACPA-IGG variable domains modulates reactivity to citrullinated antigens. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A19.2-A19.	0.5	0
194	FR10402...Cluster Analysis of an ARRAY of Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus (NPSLE). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 532.3-533.	0.5	0
195	A1.49...Anti-carbamylated protein antibodies (ANTI-CARP) precede the onset of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A21.1-A21.	0.5	0
196	Five decades of Dutch immunology. <i>Immunology Letters</i> , 2014, 162, 83-84.	1.1	0
197	A1.29...In rheumatoid arthritis, smoking is not primarily associated with anti-citrullinated protein antibodies, but with the presence of several autoantibodies. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A12.1-A12.	0.5	0
198	A7.4...The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, A76.1-A76.	0.5	0

#	ARTICLE	IF	CITATIONS
199	THU0040â€¦.In Rheumatoid Arthritis, Smoking is not Associated with Anti-Citrullinated Protein Antibodies (ACPA) Per SE, but with the Concurrent Presence of Rheumatoid Factor, Acpa and Anti-Carbamylated Protein Antibodies. Annals of the Rheumatic Diseases, 2015, 74, 206.4-207.	0.5	0
200	AB0086â€¦.Anti-Citrullinated Protein Antibodies in Patients with Cardiovascular Disease without RA. Annals of the Rheumatic Diseases, 2016, 75, 926.1-926.	0.5	0
201	A2.05â€¦.Carbamylated autoantigens facilitate the break of tolerance: A novel mechanism in the pathogenesis of autoimmune arthritis. Annals of the Rheumatic Diseases, 2016, 75, A17.1-A17.	0.5	0
202	A2.10â€¦.The isotype and subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2016, 75, A19.1-A19.	0.5	0
203	Excretions/secretions from medicinal larvae (Lucilia sericata) inhibit complement activation by two mechanisms. Immunobiology, 2016, 221, 1137.	0.8	0
204	A5.09â€¦.Mri-detected osteitis is not associated with the presence or level of ACPA alone, but with the combined presence of ACPA and RF. Annals of the Rheumatic Diseases, 2016, 75, A44.3-A45.	0.5	0
205	A2.15â€¦.Ra phenotype at presentation differs among patients with few versus many autoantibodies. Annals of the Rheumatic Diseases, 2016, 75, A21.1-A21.	0.5	0
206	AB0066â€¦.MRI-Detected Osteitis Is Not Associated with The Presence or Level of ACPA Alone, but with The Combined Presence of ACPA and RF. Annals of the Rheumatic Diseases, 2016, 75, 919.2-920.	0.5	0
207	08.26â€¦.The prevalence of acpa is lower in rheumatoid arthritis patients with a higher age of onset but the composition of the acpa response appears identical. , 2017, , .		0
208	THU0068â€¦.The risk of individual autoantibodies, autoantibody combinations and autoantibody levels for arthritis development in clinically suspect arthralgia. , 2017, , .		0
209	AB0084â€¦.Breadth of baseline autoantibody profile and treatment response in rheumatoid arthritis patients. , 2017, , .		0
210	Complement System. , 2017, , 355-365.		0
211	P026â€¦.Baseline autoantibody profile in rheumatoid arthritis associates with early treatment response but not long-term outcomes. , 2018, , .		0
212	P007â€¦.In ra, becoming seronegative over the 1st year of dmard treatment does not translate to better chances of drug-free remission in the long-term. , 2018, , .		0
213	SAT0579â€¦.Presence of autoantibodies in erosive hand osteoarthritis and association with clinical presentation. , 2018, , .		0
214	AB0113â€¦.ANTI-CARBAMYLATED PROTEIN ANTIBODIES POSITIVITY AND DISEASE ACTIVITY IN HISPANIC PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS: AN OBSERVATIONAL STUDY. Annals of the Rheumatic Diseases, 2021, 80, 1085-1086.	0.5	0
215	Antiâ€œIq autoantibodies may not serve as an adequate biomarker for lung manifestations in systemic sclerosis: a singleâ€œcentre, crossâ€œsectional study. British Journal of Dermatology, 2021, 185, 657-658.	1.4	0
216	Anti-carbamylated protein antibodies positivity and disease activity in Hispanic patients with established rheumatoid arthritis: An observational study. Modern Rheumatology, 2022, 32, 330-337.	0.9	0

#	ARTICLE	IF	CITATIONS
217	FRI0337â€¦anti-C1Q Autoantibodies, C1Q Circulating Immune Complexes and Complement Levels in Patients with Neuropsychiatric Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 2016, 75, 556.3-557.	0.5	0
218	THU0069â€¦In ra, becoming seronegative over the 1st year of dmard treatment does not translate to better chances of sustained drug-free remission in the long-term. , 2018, , .		0
219	Anti-carbamylated protein antibodies: are they useful for the diagnosis of rheumatoid arthritis?. Clinical and Experimental Rheumatology, 2021, 39, 146-150.	0.4	0